Xebio Holdings Co. Ltd. said its normalized net income for the fiscal fourth quarter ended March 31 amounted to ¥11.58 per share, a decline of 74.9% from ¥46.21 per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥521.9 million, a decline of 75.0% from ¥2.08 billion in the prior-year period.

The normalized profit margin dropped to 1.0% from 3.8% in the year-earlier period.

Total revenue declined year over year to ¥53.05 billion from ¥55.13 billion, and total operating expenses came to ¥52.59 billion, compared with ¥52.22 billion in the year-earlier period.

Reported net income came to a loss of ¥967.4 million, or a loss of ¥21.45 per share, compared to income of ¥1.32 billion, or ¥29.25 per share, in the year-earlier period.

For the year, the company's normalized net income totaled ¥92.58 per share, a fall of 50.0% from ¥185.30 per share in the prior year.

Normalized net income was ¥4.18 billion, a decrease of 50.0% from ¥8.36 billion in the prior year.

Full-year total revenue increased from the prior-year period to ¥210.67 billion from ¥204.78 billion, and total operating expenses rose 6.5% on an annual basis to ¥205.02 billion from ¥192.48 billion.

The company said reported net income fell 68.5% on an annual basis to ¥2.08 billion, or ¥46.17 per share, in the full year, from ¥6.62 billion, or ¥146.67 per share.

As of June 26, US$1 was equivalent to ¥123.96.